Understand the source comparison
Do Peptides Help With Autoimmune: Comparison
Thymalin Restores thymic epithelial function; increases Treg differentiation Systemic lupus, Hashimoto's thyroiditis, rheumatoid arthritis, multiple sclerosis Subcutaneous or intramuscular 10–20mg twice weekly Multiple controlled trials; 1,800+ patients; publi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- Restores thymic epithelial function; increases Treg differentiation
- Systemic lupus, Hashimoto's thyroiditis, rheumatoid arthritis, multiple sclerosis
- Subcutaneous or intramuscular 10–20mg twice weekly
- Multiple controlled trials; 1,800+ patients; published meta-analysis
- Strongest evidence for immune restoration in thymic involution-related autoimmune conditions
- KPV
- Inhibits NF-κB translocation; blocks pro-inflammatory cytokine transcription
- Inflammatory bowel disease, rheumatoid arthritis, psoriasis
- Subcutaneous 500mcg–2mg daily or oral delayed-release
- Phase II human trial in IBD; extensive murine data
- Best evidence for localised inflammatory control; less data on systemic autoimmune
- Cartalax
- Modulates cartilage matrix synthesis; reduces MMP-13 expression
- Rheumatoid arthritis, osteoarthritis (secondary autoimmune involvement)
- Subcutaneous 5–10mg daily for 10–20 days
- Preclinical cartilage protection studies; limited autoimmune-specific trials
- Promising for joint protection in RA but lacks large-scale autoimmune trials
- LL-37 (derived peptides)
- Antimicrobial and immune-modulating cathelicidin fragment
- Infections triggering autoimmune flares (molecular mimicry contexts)
- Topical or subcutaneous research formulations
- Mechanism studies; no large autoimmune trials
- Theoretical benefit in infection-triggered autoimmunity; insufficient clinical data
- Thymalin demonstrates the most consistent clinical benefit across multiple autoimmune conditions where thymic involution contributes to Treg deficiency. KPV's mechanism suits inflammatory autoimmune manifestations but lacks the systemic immune restoration Thymalin provides. Cartalax Peptide shows tissue-protective effects in joint autoimmunity but hasn't been studied as immune modulators in the same depth.